Prothena Corporation plc Announces Clinical Data To Be Presented At The International Symposium On Amyloidosis
3/19/2014 9:27:58 AM
DUBLIN, March 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana.
Help employers find you! Check out all the jobs and post your resume.
comments powered by